Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=485 Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is…
Phase 3 N=227 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change in the MADRS10 Total Score From Baseline to Day 28 — -15.1; -12.9 score on a scale
Phase 2 N=63 A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Cytokine Release Syndrome
Primary: Percentage of Participants Who Developed ≥Grade 2 Cytokine Release Syndrome (CRS) by Day 14 After Immune Effector Cell (IEC) Therapy, Assessed by Using American Society…
N/A N=46 Morning Light Treatment for Traumatic Stress: The Role of Amygdala Reactivity
Stress
Primary: Change in Amygdala Reactivity as Measured by Blood-oxygen-level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal — 0.1287; 0.1532; 0.2134; 0.1048…
N/A N=317 Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Community Acquired Pneumonia · Complicated Skin and Soft Tissue Infection
Primary: Number of Participants With Clinical Response — 151; 118 Participants
Phase 2 N=33 APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Primary: To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT). — 12.5 months
Phase 1 N=66 A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.
Healthy
Primary: Single Rising Dose (SRD): Percentage of Subjects With Drug-related Adverse Events. — 0.0; 11.1; 0.0; 0.0 Percentage of participants
N/A N=57 A+ Treatment/Feasibility of Adapted ESDM-informed Caregiver Coaching Delivered Remotely for Children With ASD (Autism Spectrum Disorder) and ADHD (Attention Deficit Hyperactivity Disorder)
Autism Spectrum Disorder · Adhd
Primary: Number of Caregivers and Staff Who Completed Individual Qualitative Interviews to Assess the Acceptability, Appropriateness, and Feasibility of the Intervention — 24; 5…
Phase 3 N=232 A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change in the MADRS10 Total Score From Baseline to Day 28 — -14.8; -13.9 score on a scale
N/A N=36 Virtual Reality Guided Imagery for Chronic Pain
Complex Regional Pain Syndromes · Back Pain
Primary: Number of Participants Who Are Recruited But Not Enrolled as Documented in Participant Log — 60 Participants
Phase 3 N=12 Pain Medicine for Wound Care Procedures
Wound Care · Pain Intensity · Hyperalgesia
Primary: Pain Intensity — 3.1; 6.8 score on a scale
N/A N=94 Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response
Generalized Anxiety Disorder
Primary: For Aim1: Baseline Generalized Anxiety Disorder Symptoms as Measured by the Generalized Anxiety Disorder - 7 Item Scale (GAD-7). — 12.85; 11.62 units on a scale — p=.088
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Phase 4 N=80 Intrathecal Opioids for Colorectal Resection
Colorectal Surgery · Pain, Postoperative · Analgesic, Opioid
Primary: Postoperative Pain Control — 4.5; 1.6; 1.75; 2.75 score on a scale